PPARgamma expression in breast cancer: clinical value and correlation with ERbeta
- PMID: 15656884
- DOI: 10.1111/j.1365-2559.2005.02056.x
PPARgamma expression in breast cancer: clinical value and correlation with ERbeta
Abstract
Aims: To examine the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in invasive breast carcinoma in relation to known clinicopathological features, ERbeta, and relapse-free and overall patient survival. PPARgamma is a ligand-activated transcriptional factor that regulates the transcription of various _target genes and has been implicated in human breast cancer.
Methods and results: We performed immunohistochemistry to detect PPARgamma, ERalpha, PR and ERbeta in 170 infiltrative breast carcinomas. The results were subjected to statistical analysis. PPARgamma was detected in the cytoplasm of 58% of breast carcinoma samples. PPARgamma did not differ with regard to any of the clinicopathological parameters except for histological grade, to which it was found to be inversely correlated (P = 0.019), and ERbeta, to which it was positively related (P = 0.016). As regards relapse-free survival, in univariate statistical analysis PPARgamma was found to exert a marginally favourable impact on all the patients (P = 0.076), but a strong one on patients with ductal carcinoma (P = 0.027), whereas Cox's regression analysis depicted PPARgamma to be an independent prognosticator for patients with ductal carcinoma (P = 0.039). No association was found between PPARgamma expression and overall survival.
Conclusion: These results indicate the favourable impact of PPARgamma expression on disease-free survival of patients with ductal breast carcinoma and its possible cooperation with ERbeta in exerting that favourable effect.
Similar articles
-
Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions.Endocr Relat Cancer. 2006 Mar;13(1):233-50. doi: 10.1677/erc.1.01075. Endocr Relat Cancer. 2006. PMID: 16601291
-
Expression of ERalpha and ERbeta in lobular carcinoma in situ.Histopathology. 2007 Jun;50(7):875-80. doi: 10.1111/j.1365-2559.2007.02689.x. Histopathology. 2007. PMID: 17543077
-
Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.Cancer Detect Prev. 2006;30(2):111-7. doi: 10.1016/j.cdp.2006.03.006. Epub 2006 May 2. Cancer Detect Prev. 2006. PMID: 16632244
-
Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma.Pathobiology. 2005;72(5):241-9. doi: 10.1159/000089418. Pathobiology. 2005. PMID: 16374068
-
Natural and Synthetic PPARγ Ligands in Tumor Microenvironment: A New Potential Strategy against Breast Cancer.Int J Mol Sci. 2020 Dec 19;21(24):9721. doi: 10.3390/ijms21249721. Int J Mol Sci. 2020. PMID: 33352766 Free PMC article. Review.
Cited by
-
Cytoplasmic Colocalization of RXRα and PPARγ as an Independent Negative Prognosticator for Breast Cancer Patients.Cells. 2022 Apr 6;11(7):1244. doi: 10.3390/cells11071244. Cells. 2022. PMID: 35406808 Free PMC article.
-
A Role for the PPARgamma in Cancer Therapy.PPAR Res. 2008;2008:314974. doi: 10.1155/2008/314974. PPAR Res. 2008. PMID: 18528521 Free PMC article.
-
Expanding Roles of De Novo Lipogenesis in Breast Cancer.Int J Environ Res Public Health. 2021 Mar 30;18(7):3575. doi: 10.3390/ijerph18073575. Int J Environ Res Public Health. 2021. PMID: 33808259 Free PMC article. Review.
-
PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.PPAR Res. 2008;2008:230893. doi: 10.1155/2008/230893. PPAR Res. 2008. PMID: 18645617 Free PMC article.
-
Clinical Use of PPARgamma Ligands in Cancer.PPAR Res. 2008;2008:159415. doi: 10.1155/2008/159415. Epub 2008 Dec 18. PPAR Res. 2008. PMID: 19125177 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
